Business context and reporting period
The supplied filing is Predictive Oncology Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2022 (filed May 12, 2022; ticker POAI). This conflicts with the request metadata, which names Axe Compute Inc.; verify the intended issuer before relying on this summary.
Predictive Oncology reports four segments: Helomics (precision oncology testing and research), zPREDICTA (tumor-specific models), Soluble (biopharmaceutical research services), and Skyline (STREAMWAY medical fluid-disposal products). Management said it planned to focus resources on Helomics and zPREDICTA.
Financial performance and condition
- Revenue: $314,568, up $34,251 (about 12%) from $280,317 in Q1 2021. Skyline generated $279,270, approximately 89% of total revenue; the company sold a net three STREAMWAY units in each period.
- Profitability: Gross profit was $205,125 versus $182,559; gross margin was about 65% in both periods. Operating loss was $3.41 million, compared with $3.78 million. Net loss was $3.37 million, compared with $3.89 million; diluted loss per share was $0.05 versus $0.11.
- Expenses: General and administrative expense fell $847,126, mainly due to lower former-CEO severance and legal/professional costs. Operations expense rose $316,259 and sales and marketing expense rose $189,826, reflecting acquired zPREDICTA/TumorGenesis activity, staffing, and commercialization efforts.
- Cash flow: Operating cash use was $3.09 million (versus $3.32 million); investing cash use was $80,243 (versus $393,121). Financing provided $86,885, compared with $30.34 million in Q1 2021. Cash declined $3.09 million during the quarter.
- Liquidity and debt: Cash and cash equivalents were $25.12 million at March 31, down from $28.20 million at year-end. Management stated there was no outstanding debt and believed existing resources could support the operating plan for the next 12 months and beyond. Total liabilities were $2.88 million, including lease and derivative liabilities. The company had $9.03 million remaining on an equity line, subject to conditions and potential dilution.
- Other balance-sheet measures: Total assets were $40.06 million and stockholders’ equity was $37.18 million. Accumulated deficit was $131.41 million. The company reported $6.86 million of zPREDICTA goodwill; Helomics goodwill had been fully impaired.
Changes versus the prior comparable period
- Revenue increased modestly, while net loss and operating loss narrowed. Skyline revenue remained the main source of sales; management reported roughly 90% of revenue came from Skyline in both quarters.
- Operating cash use improved by about $228,000, but Q1 2021 financing had provided $30.34 million, versus only $86,885 in Q1 2022.
- Weighted-average common shares rose to 65.84 million from 36.51 million, reflecting substantial prior-period equity issuance. The March 2022 quarter included 120,000 shares issued under the equity line.
- Management attributed expense changes to lower prior-year severance and professional fees, offset by increased operating and commercialization spending. zPREDICTA was acquired in November 2021.
Outlook, risks, and unusual items
- No numerical revenue or earnings guidance was provided. Management said cash resources were sufficient for its operating plan for at least 12 months, while also identifying financing needs, negative operating cash flow, and possible future equity or debt financing as risks. Additional equity-line use could dilute shareholders.
- COVID-19 had disrupted STREAMWAY parts supply and order fulfillment, reduced on-site efficiency, constrained sales visits, slowed receivables, and led suppliers to request deposits. The extent and duration of effects remained uncertain.
- The company reported ongoing losses and stated that it had never generated enough revenue to fund its capital requirements. Risks include customer adoption, competition, regulatory requirements, intellectual property, acquisition integration and impairment, and access to financing.
- There was no income-tax provision because of cumulative losses and a full valuation allowance on deferred tax assets. The company had not completed a Section 382 analysis of potential limits on net operating loss carryforwards.
- No legal proceedings or material related-party transactions were reported. Management stated disclosure controls were effective at quarter-end.
Important facts for investors to verify
- Confirm the issuer: the filing names Predictive Oncology Inc., not Axe Compute Inc.
- Assess whether cash, operating cash burn, and conditional equity-line availability support the operating plan, and whether further financing would be materially dilutive.
- Track revenue growth and customer adoption beyond Skyline, especially in Helomics and zPREDICTA, against management’s stated strategic focus.
- Review COVID-related supply and sales disruptions, zPREDICTA integration, and the risk of further asset impairment.
- Check the share count and potential dilution from outstanding warrants, options, preferred stock, equity-line draws, and later issuances. The filing reported 66,152,747 common shares outstanding as of May 3, 2022.